Clinical Trials Browser

Completed × acalabrutinib × Other hematologic neoplasm × Clear all

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04008706 2025-12-01

ASSURE

Phase 3 Completed

552 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04883749 2025-06-08

CLL-Frail

Phase 2 Completed

53 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

Phase 2 Completed

46 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT04930536 2024-11-22

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Phase 4 Completed

103 enrolled 10 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03788291 2024-09-26

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Phase 2 Completed

39 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

KEYNOTE145

ASSURE

CLL-Frail

CLL2-BAAG

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma